drugset

drugset / Trial / NCT02532764

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

NCT02532764 ↗

Phase 1/2 Completed 70 enrolled ProQR Therapeutics European Commission · collab

RandomizedSingle-groupTriple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.

Timeline

Start: 2015-06
Primary completion: 2017-09-14
Completion: 2017-09-14

Publications

Miah KM, Hyde SC, Gill DR. Emerging gene therapies for cystic fibrosis. Expert Rev Respir Med. 2019 Aug;13(8):709-725. doi: 10.1080/17476348.2019.1634547. Epub 2019 Jun 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ELUFORSEN	Antisense oligonucleotide	—	Other

Indications